Ivermectin Substipharm (Ivermectin)

Ivermectin binds to glutamate‑gated chloride channels in the nervous and muscular systems of parasites. This binding increases chloride ion flow, causing hyperpolarisation, paralysis, and ultimately death of the parasite, thereby interrupting its life cycle.

The dosage of Ivermectin Substipharm is determined by the prescribing clinician based on the specific indication, patient weight, age, and clinical condition. Only a qualified healthcare professional should set the appropriate dose and schedule.

Safety data for Ivermectin Substipharm in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and to consider possible exposure to a nursing infant before prescribing.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivermectin offers a broad‑spectrum oral option for several helminth and ectoparasite infections, often with a convenient single‑dose regimen. Compared with alternatives such as albendazole or praziquantel, ivermectin may be preferred for onchocerciasis and scabies, while other agents may be chosen based on parasite susceptibility and regional resistance patterns.

Ivermectin Substipharm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability and potency.

The medication is administered orally, typically as a tablet or capsule taken with water. The exact method of administration, including whether it should be taken with food, is determined by the prescribing clinician based on the indication and patient factors.

Serious adverse reactions, although rare, can include severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and anaphylaxis. Patients should be monitored for any signs of these conditions and seek immediate medical attention if they occur.

Ivermectin Substipharm should be avoided in individuals with known hypersensitivity to ivermectin or any excipients in the formulation. Caution is also advised for patients with severe hepatic or renal impairment, and it is generally contraindicated during pregnancy unless clearly indicated by a physician.